Related Experiment Video
Updated: Mar 24, 2026
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world
Yuko Kanbayashi1,2,3, Takeshi Ishikawa2,4, Hayato Kawachi2,3
1Department of Evaluation for Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Japan.
Aim:
This retrospective study aimed to identify clinical factors associated with the long-term continuation of anamorelin hydrochloride in real-world clinical practice.
Patients And Methods:
We analyzed 173 patients with lung, gastric, colorectal, or pancreatic cancer who received anamorelin hydrochloride between May 2021 and May 2025. Clinical variables potentially associated with long-term anamorelin continuation were extracted from medical records. Patients were categorized into three groups according to treatment duration: <3 weeks, 3 to <12 weeks, and ≥12 weeks. Univariate and multivariate ordered logistic regression analyses were performed to identify predictors of continued anamorelin use.
Results:
Multivariate analysis identified the Modified Glasgow Prognostic Score (mGPS) (odds ratio [OR] = 0.659, 95% confidence interval [CI] = 0.472- 0.920; p = 0.014), gastric cancer (OR =0.333, 95% CI = 0.135- 0.821; P = 0.017), and Eastern Cooperative Oncology Group Performance Status (ECOG PS) (OR =0.616, 95% CI = 0.448- 0.847; p = 0.003) as significant predictors.
Conclusion:
Lower mGPS, and better ECOG PS were associated with longer continuation of anamorelin, whereas patients with gastric cancer showed a tendency toward shorter duration. These findings provide guidance for patient selection and tailored supportive care in clinical practice.
